688029.SH
南微医学
SSE · Healthcare · Medical - Instruments & Supplies · CN
CNY 73.85
−0.39%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.3B | 3.2B | 2.8B | 2.4B | 2.0B |
| Cost of Revenue | 1.2B | 1.1B | 891.3M | 856.0M | 773.2M |
| Gross Profit | 2.1B | 2.0B | 1.9B | 1.6B | 1.2B |
| Operating Expenses | |||||
| R&D Expense | 207.8M | 199.0M | 174.4M | 150.8M | 165.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 442.5M | 433.6M | 368.8M | 328.7M | 309.1M |
| Selling & Marketing Expense | 768.7M | 746.0M | 646.3M | 572.5M | 433.3M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.4B | 1.3B | 1.2B | 998.3M | 863.0M |
| Cost and Expenses | 2.7B | 2.5B | 2.1B | 1.9B | 1.6B |
| Operating Income (EBIT) | 675.4M | 691.7M | 659.4M | 554.7M | 364.2M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 675.4M | 691.2M | 659.8M | 564.9M | 367.9M |
| Income Tax Expense | 111.3M | 108.6M | 91.7M | 70.2M | 35.1M |
| Bottom Line | |||||
| Net Income | 555.9M | 570.3M | 553.2M | 485.9M | 330.5M |
| Earnings from Cont. Ops | 564.1M | 582.6M | 568.1M | 494.7M | 332.8M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 555.9M | 570.3M | 553.2M | 485.9M | 330.5M |
| Per Share | |||||
| Basic EPS | CN¥2.97 | CN¥3.05 | CN¥2.95 | CN¥2.59 | CN¥1.77 |
| Diluted EPS | CN¥2.97 | CN¥3.05 | CN¥2.95 | CN¥2.59 | CN¥1.75 |
| Revenue Per Share | CN¥17.78 | CN¥17.03 | CN¥14.69 | CN¥12.85 | CN¥10.60 |
| Shares | |||||
| Basic Shares Outstanding | 187.8M | 187.0M | 187.5M | 187.6M | 186.7M |
| Diluted Shares Outstanding | 187.8M | 187.0M | 187.5M | 187.6M | 186.7M |
| Profitability Metrics | |||||
| EBITDA | — | 817.0M | 747.3M | 627.8M | 433.0M |
| D&A | — | 125.3M | 87.9M | 73.2M | 68.8M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026